High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer
Cancer Genomics - Proteomics · 2025
DOI: 10.21873/cgp.20520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2025. Verfasst von Yuka Nagashima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan. Hauptthemen laut MEDLINE: Protein Kinase C, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: The relationship between protein kinase C zeta (PKCζ) expression and medical treatment resistance in breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship using disease-specific survival. MATERIALS AND METHODS: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and Kaplan-Meier survival and Cox proportional hazard analyses were performed. RESULTS: High expression of PKCζ indicated a poor prognosis in patients with luminal B type treated with endocrine therapy and aromatase inhibitor as endocrine therapy. Furthermore, catenin beta interacting protein 1 (CTNNBIP1) was identified as a differentially expressed gene between the PKCζ high and PKCζ low luminal B breast cancer cohorts treated with endocrine therapy and aromatase inhibitors. PKCζ high CTNNBIP1 high luminal B breast cancer treated with endocrine therapy and aromatase inhibitor indicated a poor prognosis. These results suggest that PKCζ and CTNNBIP1 are involved in breast cancer progression and contribute to reduced susceptibility to endocrine therapy in the luminal B breast cancer subtype. CONCLUSION: PKCζ and CTNNBIP1 may serve as a prognostic biomarker for predicting the efficacy of endocrine therapy in the luminal B breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
- Laboratory of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan; akimoto@rs.tus.ac.jp k.sasaki.yb@juntendo.ac.jp.
- Laboratory of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.
- Research Division of Medical Data Science, Research Institute for Science and Technology, Tokyo University of Science, Chiba, Japan.
- Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan; akimoto@rs.tus.ac.jp k.sasaki.yb@juntendo.ac.jp.
Zitieren
APA
Nagashima, Y., Sasaki, K., Chiwaki, R., Ishii, H., Nohata, K., Maemura, Y., Kasai, T., Ozaki, A., Tamori, S., Ohno, S., & Akimoto, K. (2025). High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20520
Vancouver
Nagashima Y, Sasaki K, Chiwaki R, Ishii H, Nohata K, Maemura Y, et al. High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Cancer Genomics - Proteomics. 2025. doi:10.21873/cgp.20520
BibTeX
@article{Nagashima2025,
author = {Nagashima, Yuka and Sasaki, Kazunori and Chiwaki, Ryosuke and Ishii, Hayato and Nohata, Kana and Maemura, Yuki and Kasai, Takahiro and Ozaki, Ayaka and Tamori, Shoma and Ohno, Shigeo and Akimoto, Kazunori},
title = {High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer},
journal = {Cancer Genomics - Proteomics},
year = {2025},
doi = {10.21873/cgp.20520}
}
EUVIMED